Assessing how gliomas respond to radiochemotherapy using MRI and genetic data
Study on Radiogenomics Features Associated With Radiochemotherapy Sensitivity in Gliomas
This study is testing how well gliomas respond to radiochemotherapy by using MRI scans and genetic information from tumor samples to help predict treatment outcomes for patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Beijing Tiantan Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06454097 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the sensitivity of gliomas to radiochemotherapy by analyzing MRI data and genetic information from tumor samples. Patients with gliomas will undergo MRI scans at various stages: before surgery, before starting treatment, and after treatment completion. The study will extract radiomics features from these MRI images and combine them with transcriptomic data obtained from RNA sequencing of tumor tissues. A machine learning model will be developed to predict treatment response based on these combined data sets.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 or older with histologically confirmed gliomas who have not received prior treatments.
Not a fit: Patients with a history of other brain tumors or previous cranial surgeries may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment plans for glioma patients, improving their outcomes.
How similar studies have performed: While similar approaches using radiogenomics have shown promise in other cancers, this specific application in gliomas is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 or older * Histologically confirmed glioma * No history of other brain tumors or previous cranial surgeries * No history of preoperative radiotherapy or chemotherapy * Available preoperative, pre-radiotherapy(postoperatively), and post-radiotherapy magnetic resonance imaging (MRI) data Exclusion Criteria: * Those who do not meet any of the inclusion criteria
Where this trial is running
Beijing, Beijing Municipality
- Beijing Tiantan Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Yinyan Wang, MD and PhD — Beijing Tiantan Hospital
- Study coordinator: Yinyan Wang, MD and PhD
- Email: tiantanyinyan@126.com
- Phone: +86 13581698953
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.